Drug Profile
Somatropin/mecasermin combination therapeutics - Genentech/Tercica
Alternative Names: Growth hormone/insulin-like growth factor-1; Increlex/NutropinAq; rhGH/rhIGF-1Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech; Tercica
- Developer Ipsen Biopharmaceuticals; Tercica
- Class Biological peptides; Growth factors; Growth hormones; Peptides
- Mechanism of Action Insulin-like growth factor I stimulants; Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Short stature; Somatotropin deficiency
Most Recent Events
- 16 Oct 2008 Tercica has been acquired by Ipsen
- 25 Jan 2008 Phase-II clinical trials in Short stature in children in USA (SC)
- 12 Jul 2007 Preclinical trials in Short stature in USA (SC)